Fabrice Le Gall

1.3k total citations
20 papers, 998 citations indexed

About

Fabrice Le Gall is a scholar working on Radiology, Nuclear Medicine and Imaging, Molecular Biology and Immunology. According to data from OpenAlex, Fabrice Le Gall has authored 20 papers receiving a total of 998 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Radiology, Nuclear Medicine and Imaging, 10 papers in Molecular Biology and 7 papers in Immunology. Recurrent topics in Fabrice Le Gall's work include Monoclonal and Polyclonal Antibodies Research (15 papers), Glycosylation and Glycoproteins Research (6 papers) and Transgenic Plants and Applications (5 papers). Fabrice Le Gall is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (15 papers), Glycosylation and Glycoproteins Research (6 papers) and Transgenic Plants and Applications (5 papers). Fabrice Le Gall collaborates with scholars based in Germany, France and Netherlands. Fabrice Le Gall's co-authors include Sergey M. Kipriyanov, Melvyn Little, Gerhard Moldenhauer, Uwe Reusch, Stefan Knackmuss, Eugene A. Zhukovsky, Ivica Fucek, J.M. Bové, M. Garnier and Melvyn Little and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Journal of Molecular Biology.

In The Last Decade

Fabrice Le Gall

20 papers receiving 908 citations

Peers

Countries citing papers authored by Fabrice Le Gall

Since Specialization

Citations

This map shows the geographic impact of Fabrice Le Gall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fabrice Le Gall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fabrice Le Gall more than expected).

Fields of papers citing papers by Fabrice Le Gall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fabrice Le Gall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fabrice Le Gall. The network helps show where Fabrice Le Gall may publish in the future.

Co-authorship network of co-authors of Fabrice Le Gall

This figure shows the co-authorship network connecting the top 25 collaborators of Fabrice Le Gall. A scholar is included among the top collaborators of Fabrice Le Gall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fabrice Le Gall. Fabrice Le Gall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19⁺tumor cells 2015 ·mAbs ·Uwe Reusch, Johannes Duell, Kristina Ellwanger, (unknown), Stefan Knackmuss, Ivica Fucek, Markus Eser, Fionnuala McAleese, (unknown), Fabrice Le Gall, Max S. Topp, Melvyn Little, Eugene A. Zhukovsky	110
2	A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30⁺tumor cells 2014 ·mAbs ·Uwe Reusch, Carmen Burkhardt, Ivica Fucek, Fabrice Le Gall, (unknown), Karin Hoffmann‐Sommergruber, Stefan Knackmuss, (unknown), Melvyn Little, Eugene A. Zhukovsky	135
3	Preclinical development of an anti-CD30/anti-CD16A bispecific tetravalent TandAb antibody for the treatment of Hodgkin lymphoma. 2012 ·Journal of Clinical Oncology ·Stefan Knackmuss, Uwe Reusch, Carmen Burkhardt, Ivica Fucek, Fabrice Le Gall, Hans‐Gerd Pauels, Melvyn Little, Eugene A. Zhukovsky	1
4	Abstract 3522: Preclinical development of an anti-CD30/anti-CD16A bispecific tetravalent TandAb antibody for the treatment of Hodgkin lymphoma 2012 ·Cancer Research ·Stefan Knackmuss, Uwe Reusch, Carmen Burkhardt, Ivica Fucek, Fabrice Le Gall, Hans‐Gerd Pauels, Eugene A. Zhukovsky, Melvyn Little	5
5	68Ga-labelled recombinant antibody variants for immuno-PET imaging of solid tumours 2010 ·European Journal of Nuclear Medicine and Molecular Imaging ·Matthias Eder, Stefan Knackmuss, Fabrice Le Gall, Uwe Reusch, Vladimir Rybin, Melvyn Little, Uwe Haberkorn, Walter Mier, Michael Eisenhut	45
6	Inhibition of Melanoma Growth by Targeting of Antigen to Dendritic Cells via an Anti-DEC-205 Single-Chain Fragment Variable Molecule 2008 ·Clinical Cancer Research ·Theron Johnson, Karsten Mahnke, (unknown), Kurt Schönfeld, Sabine Ring, Dirk M. Nettelbeck, Hidde J. Haisma, Fabrice Le Gall, Roland E. Kontermann, Alexander Enk	55
7	Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody 2004 ·Protein Engineering Design and Selection ·Fabrice Le Gall, Uwe Reusch, Melvyn Little, Sergey M. Kipriyanov	63
8	Single‐chain antibodies for the conformation‐specific blockade of activated platelet integrin α _IIb β ₃ designed by subtractive selection from naïve human phage libraries 2004 ·The FASEB Journal ·Meike Schwarz, (unknown), Yoshikazu Takada, Fabrice Le Gall, Stefan Knackmuss, Nicole Bassler, (unknown), Melvyn Little, Christoph Bode, Karlheinz Peter	63
9	Generation and Production of Engineered Antibodies 2004 ·Molecular Biotechnology ·Sergey M. Kipriyanov, Fabrice Le Gall	55
10	Effect of tetravalent bispecific CD19×CD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells 2004 ·International Journal of Cancer ·Uwe Reusch, Fabrice Le Gall, Manfred Hensel, Gerhard Moldenhauer, Anthony D. Ho, Melvyn Little, Sergey M. Kipriyanov	24
11	Transformation of tobacco plants for single-chain antibody expression via apoplastic and symplasmic routes, and analysis of their susceptibility to stolbur phytoplasma infection 2004 ·Plant Science ·Sylvie Malembic-Maher, Fabrice Le Gall, Jean-Luc Danet, François Dorlhac de Borne, J.M. Bové, (unknown)	18
12	Recent advances in the generation of bispecific antibodies for tumor immunotherapy. 2004 ·PubMed ·(unknown), Fabrice Le Gall	22
13	Immunosuppressive properties of anti-CD3 single-chain Fv and diabody 2003 ·Journal of Immunological Methods ·Fabrice Le Gall	30
14	Effect of Domain Order on the Activity of Bacterially Produced Bispecific Single-chain Fv Antibodies 2003 ·Journal of Molecular Biology ·Sergey M. Kipriyanov, Gerhard Moldenhauer, Michael Braunagel, Uwe Reusch, Björn Cochlovius, Fabrice Le Gall, (unknown), (unknown), Melvyn Little	49
15	Synergistic Antitumor Effect of Bispecific CD19 × CD3 and CD19 × CD16 Diabodies in a Preclinical Model of Non-Hodgkin’s Lymphoma 2002 ·The Journal of Immunology ·Sergey M. Kipriyanov, Björn Cochlovius, Holger Schäfer, Gerhard Moldenhauer, (unknown), Fabrice Le Gall, Stefan Knackmuss, Melvyn Little	66
16	Of mice and men: hybridoma and recombinant antibodies 2000 ·Immunology Today ·Melvyn Little, Sergey M. Kipriyanov, Fabrice Le Gall, Gerhard Moldenhauer	99
17	Di‐, tri‐ and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding 1999 ·FEBS Letters ·Fabrice Le Gall, Sergey M. Kipriyanov, Gerhard Moldenhauer, Melvyn Little	103
18	Engineering of a Single-Chain Variable-Fragment (scFv) Antibody Specific for the Stolbur Phytoplasma (Mollicute) and Its Expression in Escherichia coli and Tobacco Plants 1998 ·PubMed Central ·Fabrice Le Gall, (unknown), M. Garnier	1
19	Engineering of a Single-Chain Variable-Fragment (scFv) Antibody Specific for the Stolbur Phytoplasma (Mollicute) and Its Expression in Escherichia coli and Tobacco Plants 1998 ·Applied and Environmental Microbiology ·Fabrice Le Gall, J.M. Bové, M. Garnier	52
20	[Modulation of cisplatin cytotoxicity by amphotericin B in six human cell lines of medullary thyroid cancer]. 1996 ·PubMed ·C. Massart, J Gibassier, Fabrice Le Gall, (unknown), (unknown), Claire Lucas	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact